Primary study · included by 1 review
Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.
Perrone 2025 · Perrone Elisabetta, Giordano Alessandro, Calcagni Maria Lucia, et al. · Cancers · 2025
Included by
The review does not say which of its outcomes this study informs.
1 including review in total.